CY1119487T1 - Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα - Google Patents

Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα

Info

Publication number
CY1119487T1
CY1119487T1 CY20171101087T CY171101087T CY1119487T1 CY 1119487 T1 CY1119487 T1 CY 1119487T1 CY 20171101087 T CY20171101087 T CY 20171101087T CY 171101087 T CY171101087 T CY 171101087T CY 1119487 T1 CY1119487 T1 CY 1119487T1
Authority
CY
Cyprus
Prior art keywords
kinazoline
suspensions
receptor
growth factor
effective growth
Prior art date
Application number
CY20171101087T
Other languages
English (en)
Inventor
David Yunzhi LI
Jiabing Wang
Zhenfan YANG
Qingbei Zeng
Xiaolin Zhang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288181&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119487(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1119487T1 publication Critical patent/CY1119487T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Η εφεύρεση σχετίζεται με ενώσεις του τύπου (I), ή ένα φαρμακευτικώς αποδεκτό άλας αυτών: Τύπος (I), οι οποίες κατέχουν ανασταλτική δράση ενάντια σε ενεργοποιητικές μεταλλαγμένες μορφές του EGFR και είναι αναλόγως χρήσιμες για την αντικαρκινική τους δράση και σε μεθόδους θεραπείας του ανθρώπινου ή ζωικού σώματος. Η εφεύρεση σχετίζεται, επίσης, με φαρμακευτικές συνθέσεις που τις περιέχουν και με τη χρήση τους στην κατασκευή φαρμάκων για χρήση στην παραγωγή αντικαρκινικών αποτελεσμάτων σε ένα θερμόαιμο ζώο, όπως ο άνθρωπος.
CY20171101087T 2013-03-06 2017-10-18 Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα CY1119487T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013072250 2013-03-06
PCT/GB2014/050655 WO2014135876A1 (en) 2013-03-06 2014-03-05 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

Publications (1)

Publication Number Publication Date
CY1119487T1 true CY1119487T1 (el) 2018-03-07

Family

ID=50288181

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101087T CY1119487T1 (el) 2013-03-06 2017-10-18 Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα

Country Status (42)

Country Link
US (4) US9066979B2 (el)
EP (2) EP3342770B1 (el)
JP (1) JP5894714B1 (el)
KR (1) KR101645112B1 (el)
CN (1) CN105209456B (el)
AP (1) AP2015008696A0 (el)
AR (1) AR095039A1 (el)
AU (1) AU2014224382B2 (el)
BR (1) BR112015020787B1 (el)
CA (1) CA2901269C (el)
CL (1) CL2015002361A1 (el)
CR (1) CR20150450A (el)
CY (1) CY1119487T1 (el)
DK (1) DK2964638T3 (el)
DO (1) DOP2015000189A (el)
ES (1) ES2642201T3 (el)
GT (1) GT201500251A (el)
HK (1) HK1216315A1 (el)
HR (1) HRP20171689T1 (el)
HU (1) HUE034568T2 (el)
IL (1) IL240578B (el)
LT (1) LT2964638T (el)
MA (1) MA38380A1 (el)
ME (1) ME03041B (el)
MX (1) MX362247B (el)
MY (1) MY186126A (el)
NI (1) NI201500123A (el)
NO (1) NO2964638T3 (el)
PE (1) PE20152000A1 (el)
PH (1) PH12015501965B1 (el)
PL (1) PL2964638T3 (el)
PT (1) PT2964638T (el)
RS (1) RS56566B1 (el)
RU (1) RU2656597C2 (el)
SG (1) SG11201506487YA (el)
SI (1) SI2964638T1 (el)
TN (1) TN2015000368A1 (el)
TW (1) TWI543977B (el)
UA (1) UA115686C2 (el)
UY (1) UY35369A (el)
WO (1) WO2014135876A1 (el)
ZA (1) ZA201507353B (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101645112B1 (ko) * 2013-03-06 2016-08-02 아스트라제네카 아베 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제
KR102339228B1 (ko) 2013-08-23 2021-12-13 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
WO2016051380A1 (en) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Crystalline form of afatinib dimaleate
US10947201B2 (en) 2015-02-17 2021-03-16 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105859641B (zh) 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN105503906B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种***并吡嗪衍生物a晶型及其制备方法
CN105503905B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种***并吡嗪衍生物b晶型及其制备方法
CN109843858B (zh) 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
CN108658946B (zh) * 2017-03-28 2020-06-16 焦玉奇 新颖的喹唑啉抑制剂
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN109721551B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法
CN109721552B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种吉非替尼的制备方法
KR20200143361A (ko) 2018-02-08 2020-12-23 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
WO2020053816A1 (en) * 2018-09-14 2020-03-19 Hanmi Pharmaceutical Co., Ltd. Crystalline forms of a quinazole compound and its hydrochloride salts
CN110903283B (zh) * 2018-09-17 2021-01-01 南京雷正医药科技有限公司 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
WO2020057403A1 (zh) * 2018-09-18 2020-03-26 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
MA55508A (fr) 2019-03-29 2022-02-09 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
CN110590683B (zh) * 2019-10-11 2022-08-19 山东四环药业股份有限公司 一种靶向药物azd3759中间体的制备方法
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN111662273A (zh) * 2020-06-22 2020-09-15 通化师范学院 一种酪氨酸激酶抑制剂azd3759的制备方法
CN111675700A (zh) * 2020-06-22 2020-09-18 通化师范学院 一种抗癌新药azd3759的制备方法
CN111848584A (zh) * 2020-07-10 2020-10-30 江南大学 一种多取代喹唑啉类化合物及其应用
CN113943273A (zh) * 2020-07-17 2022-01-18 上海天慈国际药业有限公司 一种肺癌药物azd3759的制备方法
CN113135901A (zh) * 2021-04-12 2021-07-20 南京雷正医药科技有限公司 氘代的喹唑啉类盐酸盐化合物的晶型及其制备和应用
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN115813927A (zh) * 2022-07-06 2023-03-21 江苏晨泰医药科技有限公司 受体酪氨酸激酶抑制剂与联苯环辛二稀木脂素的联合用药及其用途
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
ES2315008T5 (es) 1998-02-24 2012-03-06 Sisters Of Providence In Oregon Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EE200200149A (et) 1999-09-21 2003-04-15 Astrazeneca Ab Kinasoliinühendid ja neid sisaldavad ravimkoostised
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP1660479A1 (en) 2003-07-29 2006-05-31 Astrazeneca AB Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
WO2005026156A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
CN1882570B (zh) 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
CN104480200B (zh) 2004-03-31 2017-12-29 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006119673A1 (fr) 2005-05-12 2006-11-16 Wenlin Huang Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
CN101175734B (zh) 2005-05-12 2011-10-12 黄文林 一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1919900A2 (de) 2005-08-22 2008-05-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
BRPI0602275A (pt) 2006-03-24 2007-11-27 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e processo para a preparação de um derivado de quinalizona
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN101367793B (zh) 2008-09-26 2013-09-11 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
WO2010061208A2 (en) 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
KR101573109B1 (ko) 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
CN106432225B (zh) 2009-12-31 2019-02-19 和记黄埔医药（上海）有限公司 某些***并吡啶化合物和***并吡嗪化合物、其组合物和其使用方法
CN101857618B (zh) 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
MY171312A (en) 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
KR101645112B1 (ko) * 2013-03-06 2016-08-02 아스트라제네카 아베 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제

Also Published As

Publication number Publication date
WO2014135876A1 (en) 2014-09-12
PH12015501965A1 (en) 2016-01-11
ZA201507353B (en) 2017-03-29
EP2964638A1 (en) 2016-01-13
MX2015011818A (es) 2016-01-08
TN2015000368A1 (en) 2017-01-03
CN105209456A (zh) 2015-12-30
AU2014224382A1 (en) 2015-09-03
AU2014224382B2 (en) 2016-11-10
HUE034568T2 (en) 2018-02-28
RU2015139513A (ru) 2017-04-10
RU2656597C2 (ru) 2018-06-06
BR112015020787B1 (pt) 2022-12-06
SG11201506487YA (en) 2015-09-29
NO2964638T3 (el) 2018-01-06
HRP20171689T1 (hr) 2018-02-23
US9718806B2 (en) 2017-08-01
AP2015008696A0 (en) 2015-08-31
IL240578A0 (en) 2015-09-24
DOP2015000189A (es) 2015-08-31
UA115686C2 (uk) 2017-12-11
JP2016511225A (ja) 2016-04-14
US20180016259A1 (en) 2018-01-18
US20140255428A1 (en) 2014-09-11
CL2015002361A1 (es) 2016-01-04
CA2901269C (en) 2022-01-18
NI201500123A (es) 2016-02-16
KR20150083782A (ko) 2015-07-20
EP2964638B1 (en) 2017-08-09
PL2964638T3 (pl) 2018-01-31
EP3342770B1 (en) 2022-03-30
MA38380A1 (fr) 2017-01-31
NZ710850A (en) 2020-09-25
CR20150450A (es) 2015-12-01
CN105209456B (zh) 2018-05-08
KR101645112B1 (ko) 2016-08-02
MY186126A (en) 2021-06-24
TW201520206A (zh) 2015-06-01
EP3342770A1 (en) 2018-07-04
UY35369A (es) 2014-08-29
PE20152000A1 (es) 2016-01-22
SI2964638T1 (sl) 2017-11-30
AR095039A1 (es) 2015-09-16
PH12015501965B1 (en) 2016-01-11
MX362247B (es) 2019-01-09
US9066979B2 (en) 2015-06-30
US20160340342A1 (en) 2016-11-24
ES2642201T3 (es) 2017-11-15
HK1216315A1 (zh) 2016-11-04
RS56566B1 (sr) 2018-02-28
US20150320751A1 (en) 2015-11-12
IL240578B (en) 2019-03-31
CA2901269A1 (en) 2014-09-12
BR112015020787A2 (pt) 2017-07-18
JP5894714B1 (ja) 2016-03-30
TWI543977B (zh) 2016-08-01
LT2964638T (lt) 2017-12-27
PT2964638T (pt) 2017-11-14
ME03041B (me) 2018-10-20
GT201500251A (es) 2017-10-09
DK2964638T3 (en) 2017-10-30
US9375432B2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1120104T1 (el) Αναστολεις της syk
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1120334T1 (el) Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1119714T1 (el) Ενωσεις αναστολεων
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
CY1118682T1 (el) Ενωσεις πυραζολης ως αναστολεις του υποδοχεα σιγμα
EA201690752A1 (ru) Ингибиторы g12c kras
CY1120881T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
PE20211548A1 (es) Compuesto de triazina y su uso para fines medicos
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου